Skip to main content
. 2022 Jul 8;6(7):e35636. doi: 10.2196/35636

Table 1.

Sample characteristics as separated by each outcome measure and analysis.

Measure Age (years) Gender, n (%) Test setting, n (%) NFTa protocols used in ≥50% of sample No. of sessions, mean (SD) Treatment duration (days), mean (SD) Frequency (sessions/wk), mean (SD)

Mean (SD) Range Female Male Clinic Home



Symptom questionnaire pre-post (n=301b) 38
(14.5)
13-71 157
(52.7)
141
(47.3)
220
(73.1)
81
(26.9)
Reduce theta;
reduce high beta;
enhance low beta
53 (38.2) 91 (41.0) 4 (2.6)
CPTc pre-post (ADHDd; n=203e) 37
(12.9)
13-69 103
(51.2)
98
(48.8)
112
(55.2)
91
(44.8)
Reduce theta;
reduce high beta
53 (29.5) 96 (42.2) 4 (1.9)
Resting EEGf baseline (adult ADHD; n=271g) 38
(10.9)
18-70 94
(35.2)
173
(64.8)
87
(32.1)
184
(67.9)
N/Ah N/A N/A N/A
Resting EEG pre-post (adult ADHD; n=41i) 36
(9.3)
19-55 17
(42.5)
23
(57.5)
5
(12.2)
36
(87.8)
Reduce theta;
enhance alpha;
reduce high beta
55 (30.8) 76 (27.0) 5 (2.2)

aNFT: neurofeedback training.

bNo gender identity was reported by 3 participants (n=298).

cCPT: continuous performance task.

dADHD: attention-deficit/hyperactivity disorder.

eNo gender identity was reported by 2 participants (n=201).

fEEG: electroencephalography.

gNo gender identity was reported by 4 participants (n=267).

hN/A: not applicable; intervention details were not reported, as only preintervention values were of interest for baseline analyses.

iNo gender identity was reported by 1 participant (n=40).